Placebo Control

Maybe those pesky sites are good for something after all.  It's been six years since Pfizer boldly announced the launch of its "...

It is becoming increasing accepted within the research community that patient engagement leads to a host of positive outcomes – most import...

Near the end of last year, I had the bright idea of starting a second blog, Placebo Lead-In , to capture a lot of smaller items that I foun...

The Wall Street Journal has an interesting article on the use of “Big Data” to identify and solicit potential clinical trial participants. ...

The authors of the study I blogged about on Monday were kind enough to post a lengthy comment, responding in part to some of the issues I ...

There has been considerable noise coming out of the UK lately about successes in clinical trial enrollment. First, a couple months ago cam...

Are we looking at our enrollment data in the right way? I will be chairing a session on Tuesday on this topic, joined by a couple of g...

Even by the already-painfully-embarrassingly-low standards of clinical trial enrollment in general, patient enrollment in cancer clinical tr...

Are competing trials slowing yours down? Probably not. If they don't like your trial, EVERYTHING ELSE IN THE WORLD is competition fo...

Last week, the Tufts Center for the Study of Drug Development unleashed the latest in their occasional series of dire pronouncements about...

Here's a fitting postscript to yesterday's article about wishful-thinking-based enrollment strategies : we received a note from a re...

The many flavors of wish-based patient recruitment. [Hopefully-obvious disclosure: I work in the field of clinical trial enrollment .] ...